UMBILICAL VEIN INJECTION OF MISOPROSTOL VERSUS NORMAL SALINE FOR THE TREATMENT OF RETAINED PLACENTA IN A TERTIARY CARE CENTRE- A NON-RANDOMISED CONTROLLED TRIAL

Kajal Kumar Patra¹, Shibram Chattopadhyay², Amarnath Dey³, Chaitali Sarkar⁴, Anaindita Chakraborty⁵, Shritanu Bhattacharyya⁶

¹Associate Professor, Department of Obstetrics and Gynaecology, Bankura Sammilani Medical College.
²Associate Professor, Department of Obstetrics and Gynaecology, Nil Ratan Sircar Medical College.
³Postgraduate Trainee, Department of Obstetrics and Gynaecology, BSMD.
⁴Postgraduate Trainee, Department of Community Medicine, North Bengal Medical College.
⁵Professor, Department of Obstetrics and Gynaecology, NRSMCH, Kolkata.

ABSTRACT

BACKGROUND
Many cases of PPH are associated with retained placenta, having great impact on maternal mortality and morbidity worldwide. The aim of our study was to evaluate the efficacy of intravumilical misoprostol versus normal saline injection as a treatment for retained placenta after vaginal delivery to reduce the incidence of manual removal of placenta and blood loss associated with it.

MATERIALS AND METHODS
It was a hospital-based, non-randomised controlled trial study carried out in the Department of Obstetrics and Gynaecology, Bankura Sammilani Medical College and Hospital, Bankura for one year period from April 2015 to March 2016. The study group of total 50 mothers received 800 mcg of misoprostol dissolved in 25 mL of normal saline and injected by Pipingas technique through umbilical vein. In control group, a total of 50 mothers received 25 mL NS injected by Pipingas technique through umbilical vein. Outcome measures were expulsion of the placenta, need for manual removal of the placenta under anaesthesia and amount of blood loss.

RESULTS
Total number of patients requiring manual removal of placenta in the entire study population (n= 100) was 26. Total 16% (n= 8) patients among misoprostol group (n= 50) underwent manual removal, while 36% (n= 18) of patients underwent manual removal of placenta in normal saline group (n= 50) which was statistically significant with p value < 0.05. In terms of duration of third stage of labour (time calculated after 30 mins) and amount of blood loss (mL), median values of both the parameters were less in misoprostol group than normal saline group and the results were statistically significant (p= 0.00).

CONCLUSION
Intravumilcal misoprostol is a promising tool for treatment of retained placenta; it acts by placing misoprostol directly to the placental bed. As per our study, we concluded that intravumilcal misoprostol significantly reduces the need for manual removal of placenta. The success rates were 84% (42/50) in intravumilcal misoprostol group compared to 64% (32/50) in saline group. The proportion of patients requiring manual removal of placenta in the intravumilcal misoprostol arm (8/50 patients, 16%) was lower than that in the intravumilcal saline arm (18/50 patients, 36%), (p value < 0.05).

KEYWORDS
Outcome, Post-Partum Haemorrhage, Intravulcal Misoprostol, Manual Removal of the Placenta, Retained Placenta, Active Management of Third Stage of Labour.


BACKGROUND
Post-partum Haemorrhage (PPH) is a significant cause of maternal mortality in the developing world. Many cases of PPH are associated with retained placenta, a condition that affects between 0.6 and 3.3% of normal deliveries.¹²³

Where there is easy access to hospital care and transfusion, mortality from this condition is very low. In many parts of the developing world, however, the case fatality rate is high.

Financial or Other; Competing Interest: None.
Corresponding Author:
Dr. Shibram Chattopadhyay,
#67 B, S.N. Banerji Road, Kolkata- 700014.
E-mail: shibramchatt@gmail.com
DOI: 10.14260/Jemds/2017/948

The retained placenta is defined as placenta remains undelivered even after 30 minutes of delivery of foetus (WHO). It is a significant cause of maternal mortality and morbidity throughout the developing world. It complicates 2% of all deliveries and has a case mortality rate of nearly 10% in rural areas.

The only effective treatment option available for a retained placenta is Manual Removal of the Placenta (MROP) under anaesthesia which requires an operation theatre setup, skilled obstetricians and anaesthetists and during this procedure the woman is exposed to the risk of the anaesthesia as well as the infective risk that comes from inserting a hand into the uterus. Both risks are higher in resource-poor countries where the prevalence of infections is high and personnel skilled in obstetrics anaesthesia are in short supply. Previously, in various studies intravulcal oxytocin given in intravumilcal vein directly places this oxytocin to retroplacental myometrium and helps in its
contraction, thereby preventing PPH and also helps in early separation of placenta. In our study, we have used Misoprostol solution instead of Oxytocin for the same purpose as Misoprostol is cheap, easily available and can be preserved easily and in room temperature.

MATERIALS AND METHODS
It was a hospital-based, non-randomised controlled trial study carried out in the Department of Obstetrics and Gynaecology, Bankura Sammilani Medical College and Hospital, Bankura, West Bengal, India, during one year period from April 2015 to March 2016. Informed consent was taken. The study was done on the patients admitted in Labour Ward for delivery. Inclusion criteria were gestational age at least 28 weeks, single live foetus with birth weight of the baby more than 1.5 kgs and patient being haemodynamically stable with systolic blood pressure < 140 mmHg and diastolic blood pressure < 90 mmHg. Criteria for retained placenta was taken as “placenta not separated after 30 mins of delivery in spite of active management of 3rd stage of labour.”

The incidence of retained placenta is 1% - 2%. The total number of deliveries in our hospital is 20,000 per year. Among the deliveries, 400 (approximately) cases of retained placenta occur annually, out of which 120 cases were admitted in our unit. So sample size is taken for convenience. Out of 120 patients, 20 patients were excluded by exclusion criteria. The study group of total 50 mothers received 800 mcg of misoprostol dissolved in 25 mL of normal saline and injected by Pipingas technique through umbilical vein. In control group, total 50 mothers received 25 mL NS injected by Pipingas technique through umbilical vein. Outcome measures were expulsion of the placenta, need for manual removal of the placenta under anaesthesia and amount of blood loss. Ethical permission from the Institutional Ethics Committee and informed consent from patient and/or relatives were taken prior to the study and interventions.

The whole data was analysed on computer based programme SPSS version 10.0. Descriptive statistics were used to present demographic status of the participants. Mean and standard deviation was calculated for continuous variables like age, parity. Percentage and frequencies were calculated for categorical variables like success versus failure of placental spontaneous expulsion. Independent ‘t’ test was also used. Chi square test was used to compare effectiveness between both groups. P ≤ 0.005 was taken as significant.

RESULTS
A total of 120 patients with retained placenta occurred at the stipulated study period. We have attended 100 retained placenta patients. Patients were equally divided into two groups. 50 patients in Group 1 received misoprostol and 50 patients of Group 2 received normal saline.

Maximum study population (62%) was in the age group of 21 - 30 years and maximum study population (49%) was primipara. Spontaneous onset of labour occurred in 66% of cases. Induction required in 10% and augmentation done in 24% cases. As per our study manual removal was required in 26% of patients, while 74% had spontaneous removal.

Manual removal of placenta was more in Group 2 (Normal Saline) (69.2%) than in Group 1 (Misoprostol) (30.8%) and the difference was statistically significant (p < 0.05).
Table 1. Distribution of Study Population according to Baseline Variables and between Two Groups (n = 100)

<table>
<thead>
<tr>
<th>Baseline Variables</th>
<th>Group 1 (Misoprostol)</th>
<th>Group 2 (Normal Saline)</th>
<th>t-value</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yrs.)</td>
<td>1 Misoprostol (n=50)</td>
<td>2 Normal saline (n=50)</td>
<td>2.28</td>
<td>0.10</td>
</tr>
<tr>
<td>Height (cm)</td>
<td>1 Misoprostol (n=50)</td>
<td>2 Normal saline (n=50)</td>
<td>153.46</td>
<td>0.07</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>1 Misoprostol (n=50)</td>
<td>2 Normal saline (n=50)</td>
<td>5.44</td>
<td>0.00</td>
</tr>
<tr>
<td>Systolic BP (mmHg)</td>
<td>1 Misoprostol (n=50)</td>
<td>2 Normal saline (n=50)</td>
<td>117.40</td>
<td>0.02</td>
</tr>
<tr>
<td>Duration of third stage of labour (time calculated after 30 mins.)</td>
<td>1 Misoprostol (n=50)</td>
<td>2 Normal saline (n=50)</td>
<td>20.68</td>
<td>0.00</td>
</tr>
<tr>
<td>Amount of blood loss (mL)</td>
<td>1 Misoprostol (n=50)</td>
<td>2 Normal saline (n=50)</td>
<td>292.00</td>
<td>2.66</td>
</tr>
<tr>
<td>Maternal post-partum Hb% level (gm)</td>
<td>1 Misoprostol (n=50)</td>
<td>2 Normal saline (n=50)</td>
<td>9.55</td>
<td>1.01</td>
</tr>
<tr>
<td>Weight of placenta (gm)</td>
<td>1 Misoprostol (n=50)</td>
<td>2 Normal saline (n=50)</td>
<td>575.80</td>
<td>0.24</td>
</tr>
</tbody>
</table>

Table 2. Distribution of Study Population according to Baseline Variables and between Two Groups (n = 100)

<table>
<thead>
<tr>
<th>Variables</th>
<th>Group 1 (Misoprostol)</th>
<th>Group 2 (Normal Saline)</th>
<th>Chi-square</th>
<th>df</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>H/O miscarriage</td>
<td>8 (16%)</td>
<td>9 (18%)</td>
<td>1.01</td>
<td>1</td>
<td>0.60</td>
</tr>
<tr>
<td>H/O D and C</td>
<td>4 (8%)</td>
<td>4 (8%)</td>
<td>0.00</td>
<td>1</td>
<td>1.00</td>
</tr>
<tr>
<td>Spontaneous labour</td>
<td>33 (66%)</td>
<td>33 (66%)</td>
<td>0.00</td>
<td>1</td>
<td>1.00</td>
</tr>
<tr>
<td>Blood transfusion</td>
<td>9 (18%)</td>
<td>18 (36%)</td>
<td>4.11</td>
<td>1</td>
<td>0.04</td>
</tr>
<tr>
<td>Parity (multi para)</td>
<td>24 (48%)</td>
<td>27 (54%)</td>
<td>0.36</td>
<td>1</td>
<td>0.54</td>
</tr>
</tbody>
</table>

DISCUSSION

This study was conducted in the Department of Gynaecology and Obstetrics, Bankura Sammilani Medical College and Hospital, Bankura from April 2015 to March 2016. In our study, maximum study population (62%) was in the age group of 21 - 30 years. The mean age in the study (intraumbilical misoprostol) and control (saline) arms were 22.84 (4.48) and 22.04 (2.43) years respectively (p value = 0.27). In a study done by Shaleen et al, the mean age of the participants did not differ significantly between the experimental and control groups (24.52 ± 5.16 years vs. 25.83 ± 4.66 years, p value = 0.374). Our study included a more homogeneous population compared to that in Shaleen et al.

As per our study, manual removal was required in 26% of patients, while 74% had spontaneous removal. Manual removal of placenta was more in Group 2 (Normal Saline) (69.2%) than in Group 1 (Misoprostol) (30.8%) and the difference was statistically significant (p < 0.05). As per Cochrane review conducted by Carroli G, Bergel E et al. compared with expectant management, umbilical vein injection of saline solution alone did not show any significant difference in the incidence of manual removal of the placenta.

The mean blood loss in our study was 292.00 mL (187.84) in misoprostol group and 408.20 mL (245.10) in saline group with significant p value (p= 0.00). The mean blood loss was 350.10 mL with standard deviation of 224.965. The median of vaginal blood loss as per Shaleen et al was 30 - 75 mL in misoprostol group and 100 - 150 mL in saline group.

In our study, the mean duration of 3rd stage of labour was 24.45 mins with standard deviation of 9.8. Compared between two groups 20.68 mins required in misoprostol group, while 28.22 mins in saline group with significant p value (< 0.05).
reported diarrhoea, which was dose related and usually developed early in the course of therapy (after 13 days) and was usually self-limiting (often resolving within 8 days), but sometimes (in 2% of patients) required discontinuation of misoprostol.

**Abbreviations**

**Limitation**
We have not estimated the sample size, but taken on convenience.

**CONCLUSION**
Retained placenta is a potentially life-threatening complication of 3rd stage of labour and associated with significant PPH. It is defined as failure of expulsion of placenta even after 30 mins of delivery of foetus. Only treatment option available till date is manual removal of placenta which requires a proper setup, surgeon and anaesthetists. These may not be available in poor resource settings and also MROP is associated with various risks.

Intraumbilical misoprostol is a promising tool for treatment of retained placenta. It acts by placing misoprostol directly to the placental bed.

As per our study, we concluded that intraumbilical misoprostol significantly reduces the need for manual removal of placenta. Our study also concluded that the amount of blood loss was lower in misoprostol group. The total amount of blood loss during placental expulsion was significantly lower in the intraumbilical misoprostol arm. Intraumbilical misoprostol also decreases the median duration of placental expulsion in cases of retained placenta and thereby decreases the duration of 3rd stage of labour significantly.

As per our study duration of hospital stay, drop in haemoglobin and post infusion complication were not statistically significant in both the arms. Only fewer patients had post infusion complications. Thus, in our study intraumbilical misoprostol appeared as an efficacious and safer tool for treatment of retained placenta. It decreases the incidence of manual removal of placenta and blood loss associated with it. It also decreases the mean duration of 3rd stage of labour by causing early separation of placenta.

**REFERENCES**